REFERENCES
- Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed July 7,2011.
- Murioz de Benito RM, Arribas Lopez JR. Tenofovir diso-proxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. Expert Rev Anti Infect Ther. 2006;4(4):523–535.
- Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2)191–201.
- McComsey GA, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection [106LB]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16–19, 2010; San Francisco, CA.
- Stellbrink H, Moyle G, Orkin C, et al. Assessment of safety and efficacy of abacavir/lamivudine and tenofo-vir/emtricitabine in treatment-naive HIV-1 infected sub-jects. ASSERT: 48-week result [PS10/1]. In: Program and abstracts of the 12th European AIDS Conference; November 11–14, 2009; Cologne, Germany.
- Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36(8):1070–1073.
- Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dys-function associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004;35(3):269–273.
- Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomeru-lar function in HIV patients treated with tenofovir. AIDS. 2009;23(6):689–696.
- Gathe J, Silva BA, Cohen DE, et al. A once-daily lopinavir/ ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009;50(5):474–481.
- Zajdenverg R, Podsadecki TJ, Badal-Faesen S, et al. Simi-lar safety and efficacy of once- and twice-daily lopinavir/ ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks. J Acquir Immune Defic Syndr. 2010;54(2)1 43–151.
- Kaletra [package insert]. North Chicago, IL: Abbott Labo-ratories; 2010.
- lsentress [package insert]. Whitehouse Station, NJ: Merck & Co; 2010.
- Lennox JL, DeJesus E, Lazzarin A, et al. Safety and effi-cacy of raltegravir-based versus efavirenz-based com-bination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised con-trolled trial. Lancet. 2009;374(9692):796–806.
- Rhame F, Long M, Acosta A. RAL-KAL: pharmacokinet-ics of coadministered raltegravir and lopinavir-ritonavir in healthy adults [TuPE0075]. Paper presented at: 17th Inter-national AIDS Conference; August 3–8, 2008; Mexico City, Mexico.
- Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17(5):138–145.
- US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval. 2002. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegula-toryInformation/Guidances/ucm070968.pdf.
- Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–2106.
- Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16(1):62–68.
- van Wyk J, Qaqish R, Hollar K, Correll T, Norton M, King M. Baseline HIV-1 RNA does not affect virologic response to lopinavir/ritonavir-based regimens in antiretroviral-naive subjects: results of a 96-week meta-analysis of >2400 subjects [THPE0067]. Presented at: XVIII International AIDS Conference; July 18–23, 2010; Vienna, Austria.
- Soulie C, Assoumou L, Ghosn J, et al. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to non-nucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. AIDS. 2009;23(12)1605–1608.